ERADICATE: Ceftobiprole Noninferior to Daptomycin for Complicated Staphylococcus aureus Bacteremia
The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.
Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS
A retrospective study of a Colombian cohort examined the causes of antiretroviral switch in people living with HIV/AIDS, as well as the time to ART switch.
Containing an Outbreak of Carbapenem-Resistant Acinetobacter baumannii in a COVID-19 Isolation Unit
COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.
COVID-19 Vaccination Protects Against Severe Clinical Outcomes in Hospitalized Adults
Overall, 91.5% of the hospitalized adults with COVID-19 were unvaccinated and 8.5% of patients were fully vaccinated.
COMBINE: Phase 1 Safety Outcomes for Ceftazidime-Avibactam in Combination With Aztreonam
A 2-hour intermittent infusion of ceftazidime-avibactam with aztreonam (ATM) is safe, but clinicians should exercise caution when prescribing continuous infusion ATM.
PREMISE: Bacterial STI Prophylaxis Failed to Cut Infection Rates for Pregnant Women Living With HIV
The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.
Cytomegalovirus Vaccine Candidate Leverages mRNA Technology to Induce ‘Robust’ Immune Response
The phase 2, randomized, placebo-controlled, dose-finding trial evaluated the mRNA-based cytomegalovirus vaccine, which features a lipid nanoparticle formulation.
Hospital Discharge a Key Opportunity to Practice Antimicrobial Stewardship
Designing a transitions of care stewardship program and engaging all stakeholders can help cut down on unnecessary antibiotic prescriptions.
Vancomycin With a β-Lactam: Comparing Acute Kidney Injury Rates of Trough vs AUC Dosing
Can clinicians rely on dosing strategy to avoid acute kidney injury for patients receiving vancomycin with a β-lactam like piperacillin-tazobactam?
Challenging Gram Negative Pathogens and Oral Carbapenems: MAD-ID Updates With Jason Pogue, PharmD
Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.
Assessing Antibiotic Prescribing Patterns in Adult Primary Care Clinics
A MAD-ID 2022 poster sought to better understand the current antibiotic prescribing patterns at adult primary care clinics affiliated with Maimonides Medical Center in New York.
Tools to Ease Non-Infectious Disease Provider Comfort Prescribing PrEP
In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing PrEP with their patients.
Examining Clostridioides difficile Incidence and Clinical Impact Across the US
In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000 patients with C diff.
How the COVID-19 Pandemic Affected Antimicrobial Stewardship
At MAD-ID 2022, Payal K. Patel, MD, MPH, FIDSA, discussed how COVID-19 misinformation and lags in diagnostics contributed to inappropriate antibiotic use and offers some way to combat this trend.
Role of the Microbiome in Preventing Recurrent C difficile Infection
Colleen R. Kelly, MD, FACG, speaks at MAD-ID 2022 on alternatives to antibiotics for C diff infection, including the use of probiotics and fecal microbiota transplantation.
Antimicrobial Stewardship Pearls to Optimize Patient Outcomes: Matthew B. Goetz, MD
“Clearly, stewardship is a team operation. It starts [with] the leadership, the clinical pharmacy, and coordination with infectious disease physicians truly has to be synergistic,” Goetz said in the keynote address at MAD-ID 2022.
FDA Approves Baricitinib for Certain Hospitalized Adults With COVID-19
The federal agency authorized the therapy as a standalone treatment via a revised EUA in July of last year.
CYPRESS Trial: RSV Vaccine for Older Adults Elicits Robust Immune Response
The findings have supported the launch of a phase 3 trial called EVERGREEN, which is now underway.
People Living With HIV Experience a Diminished Immune Response to COVID-19 mRNA Vaccines
Major predictors of response were CD4+ count, suppressed viral load, and whether the participant received the Moderna or Pfizer mRNA vaccine.
PROVENT Trial: AZD7442 as Long-Acting Pre-Exposure Prophylaxis Protects Against Symptomatic COVID-19
In the primary efficacy analysis, the risk of developing symptomatic COVID 19 was reduced by 77% with AZD7442.
Identifying Deficiencies in Nursing Home Antibiotic Stewardship Implementation
In research presented virtually at IDWeek 2021, investigators with the Centers for Disease Control and Prevention (CDC) conducted a review of nursing home antibiotic stewardship citation deficiencies in order to improve implementation.
Lenzilumab Significantly Improves COVID-19 Survival Without Invasive Ventilation
In newly hospitalized hypoxic patients with COVID-19, the monoclonal antibody significantly improved survival without invasive mechanical ventilation compared with placebo and available treatments, according to phase 3 trial results.
Cardiovascular Disease Diagnoses Remain Elevated 3 Months After COVID-19 Infection
“Compared to the pre-COVID period, the odds ratio for CVD encounters was nearly doubled in each post-COVID period from 31 to 90 days post onset,” Brian Agan, MD, deputy science director and HIV research director of the Infectious Disease Clinical Research Program at USU/HJF and presenting author, told Contagion®.
Rates of Invasive Pulmonary Aspergillosis in ICU Patients With Influenza Far Lower Than Previously Thought
The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224).
Long-Term Care Facility Residence Associated With Atypical Presentation of COVID-19
Reports of hospitalized older adults with COVID-19 who do not experience the classic symptoms are on the rise.
Fosmanogepix Shows Promise as an Effective Novel Antifungal in POC Trial
“The compound appears to be safe and well-tolerated, [and we observed] excellent efficacy based on a very small sample size,” Peter G. Pappas, MD, said.
Antibiotic Stewardship in the Urgent Care Setting Cuts Antibiotic Prescribing for Respiratory Encounters
The urgent care setting is a prime target for antimicrobial stewardship efforts as it becomes an increasingly prevalent form of healthcare delivery.
20-Valent Pneumococcal Conjugate Vaccine Comparable to Prevnar 13 in Phase 3 Study
In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.
POLAR Study: Switch to Long-Acting Cabotegravir-Rilpivirine Every 2 Months Is Safe, Tolerable
Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.
BRAAVE 2020: Biktarvy Noninferior as a Switch Treatment for Black Americans Living With HIV
The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.
2 Clarke Drive Cranbury, NJ 08512